AL-SHADOWDRAGON
14.4.2024 18:01:30 CEST | Business Wire | Press release
ShadowDragon™, a provider of ethical open-source intelligence (OSINT) software, unique datasets and APIs, is pleased to announce significant enhancements to its flagship Open-Source Intelligence Investigative platform Horizon®. These updates represent a milestone in the evolution of investigative technology, offering capabilities to streamline investigative processes and uncover valuable insights.
The OSINT Platform encompasses an all-in-one solution for investigations with unparalleled access to publicly available information, including geolocation data, platform monitoring, breach data and the ability to integrate external data streams. This allows for a modern approach to link analysis in one comprehensive toolkit. Horizon® offers access to more than 225 data collection sources, more than 1500 pivot points, and advanced, customizable link analysis capabilities.
Horizon® is accessible with any internet connection and allows users to access critical data and conduct investigations from any device, providing unprecedented flexibility and mobility. Mapping advancements, plotting capability, visual geofencing, and geoestimation allow for different starting points that pinpoint precise locations and uncover valuable insights. Horizon® offers unmatched ease of integration, creating tailored data streams able to solve for any problem set. Horizon® will also enable analysts the ability to work on the go from a tablet, phone, or desktop/laptop.
Horizon®, coupled with ShadowDragon’s SocialNet ® offers a powerful OSINT toolkit that includes more than 225 data collection sources to use for correlating publicly available data, integrated brand monitoring, breach data inquiries, social media information and link analysis capabilities to empower users with a holistic approach to investigations. Users benefit from advanced link analysis capabilities, allowing them to connect the dots and uncover actionable intelligence with ease.
CEO Daniel Clemens said, “Our customers have asked for a unified platform for many years. We are answering their requests with Horizon®, enabling customers to use our platform and data with their existing tools, easily import and export data, while enabling greater focus for complex analysis of data. The Horizon® Platform allows publicly available data to tell the story for the analyst. I am very delighted at what our team has produced and thankful to how our tools help protect many on a global scale.”
“You guys are doing incredible things with SocialNet® and Horizon®. Looking back as a user of Horizon's early release, it has been the coolest privilege to experience the last three years of innovation, watching the platform evolve and morph with every incremental update, and knowing there are always more tweaks still in the works.” - Law Enforcement Customer.
These updates underscore ShadowDragon's commitment to innovation and excellence in the field of investigative technology. By continuously enhancing its OSINT suite with new features, data collection sources and capabilities, ShadowDragon aims to empower investigators with the tools they need to stay ahead of emerging threats and make informed decisions.
Nico Dekens, ShadowDragon Director of Intelligence, said, "This is as close as one can get to having a silver bullet solution that helps solve investigative and analytical needs. This means that no matter what OSINT expertise you have, ShadowDragon's technology will speed up your investigation through an initiative platform. But it is not limited to just the platform and tools, the seasoned team will train you on usage and will support you in getting the most out of your investigative needs. The newly released features and capabilities will make your work future proof and will speed up ANY investigation significantly."
For more information about the ShadowDragon™ suite of OSINT tools and capabilities, such as SocialNet®, OIMonitor®, MalNet®, and Horizon®, click here.
About ShadowDragon
ShadowDragon™ provides comprehensive, cyber investigative resources and training for use by private companies, intelligence gathering professionals, law enforcement, and government. The U.S.-based company delivers open source intelligence (OSINT) from over 225 networks including social media platforms, chat rooms, forums, historical datasets, and the dark web. The company monitors malware history, data breach dumps, and other areas for active cyber threats. These data collection and analytic tools help defend against malicious acts in the digital and physical world. For more information, visit www.shadowdragon.io. Visit the ShadowDragon Trust Center for details about the company’s approach to “OSINT for Good”.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240413210644/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
